Abstract: The present invention relates to a formulation of Spinacea oleracea useful for the prevention or treatment of osteo-health related disorders. The present invention relates to the field of pharmaceutical formulation that provides extract, fractions, pure compound isolated from natural sources and formulation thereof useful for the prevention and treatment of various medical indications. Further, this invention relates to conditions associated with estrogen dependent or independent diseases (primary/secondary osteoporosis) or syndromes or disorders preferably relating to cartilage such as osteoarthritis caused in humans and animals. Furthermore, this invention relates to achievement of peak bone mass during skeletal growth and health in humans and animals.

Abstract: A plurality of first controllers operate according to a plurality of access protocols to control a plurality of memory modules. A second controller receives access requests that target the plurality of memory modules and selectively provides the access requests and control information to the plurality of first controllers based on physical addresses in the access requests. The second controller generates the control information for the first controllers based on statistical representations of the access requests to the plurality of memory modules.

Abstract: A cache controller to configure a portion of a first memory as cache for a second memory responsive to an indicator of locality of memory access requests to the second memory. The indicator of locality determines a probability that a location of a memory access request to the second memory is predictable based upon at least one previous memory access request. The cache controller may determine a size of the cache based on a value of the indicator of locality or modify the size of the cache in response to changes in the value of the indicator of locality.

Abstract: This invention relates in general to a system, apparatus, and method comprises one or more mapping and modeling systems used for power estimation, management, and improved efficiencies for the integrated circuit.

Abstract: The present invention relates to a preparation method of implant comprising drug delivery layer and implant composition for living donor transplantation comprising the same, and more specifically, a preparation method of implant comprising drug delivery layer comprising preparing chitosan-bioactive glass composite solution; preparing drug-containing complex coating composition by adding drug in the chitosan-bioactive glass composite solution; and preparing drug delivery layer by electrophoresis of the complex coating composition on the surface of implant, and implant composition for living donor transplantation comprising the same. The implant composition according to the present invention is able to deliver the drug, and therefore to prevent inflammation, which may occur after the surgery, as well as to promote recovery depending on the type of drugs contained.

Abstract: The present invention provides a method of treating Restless Legs Syndrome in human or animal patient, which method comprises administering to said patient an effective amount of ropinirole or a pharmaceutically acceptable salt or solvate thereof. Preferably, a dose of ropinirole or a pharmaceutically acceptable salt or solvate thereof is administered to the patient 1 to 3 hours before the patient goes to bed. A typical dose comprises 0.1 mg-5 mg of ropinirole. The invention also provides a pharmaceutical composition for use in the treatment of Restless Legs Syndrome which comprises an effective amount of ropinirole or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier.

Abstract: The present invention provides a method of treating Restless Legs Syndrome in human or animal patient, which method comprises administering to said patient an effective amount of ropinirole or a pharmaceutically acceptable salt or solvate thereof. Preferably, a dose of ropinirole or a pharmaceutically acceptable salt or solvate thereof is administered to the patient 1 to 3 hours before the patient goes to bed. A typical dose comprises 0.1 mg -5 mg of ropinirole. The invention also provides a pharmaceutical composition for use in the treatment of Restless Legs Syndrome which comprises an effective amount of ropinirole or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier.

Abstract: The present invention provides a method of treating Restless Legs Syndrome in human or animal patient, which method comprises administering to said patient an effective amount of ropinirole or a pharmaceutically acceptable salt or solvate thereof. Preferably, a dose of ropinirole or a pharmaceutically acceptable salt or solvate thereof is administered to the patient 1 to 3 hours before the patient goes to bed. A typical dose comprises 0.1 mg-5 mg of ropinirole. The invention also provides a pharmaceutical composition for use in the treatment of Restless Legs Syndrome which comprises an effective amount of ropinirole or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier.

Abstract: The present invention provides a method of treating Restless Legs Syndrome in human or animal patient, which method comprises administering to said patient an effective amount of ropinirole or a pharmaceutically acceptable salt or solvate thereof. Preferably, a dose of ropinirole or a pharmaceutically acceptable salt or solvate thereof is administered to the patient 1 to 3 hours before the patient goes to bed. A typical dose comprises 0.1 mg-5 mg of ropinirole. The invention also provides a pharmaceutical composition for use in the treatment of Restless Legs Syndrome which comprises an effective amount of ropinirole or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier.